Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Osteosarcoma: the COSS experience
JournalItem (Reviews, Editorials, Rezensionen, Urteilsanmerkungen etc. in einer wissenschaftlichen Zeitschrift)
 
ID 1197411
Author(s) Bielack, Stefan; Juergens, Herbert; Jundt, Gernot; Kevric, Matthias; Kuehne, Thomas; Reichardt, Peter; Zoubek, Andreas; Werner, Mathias; Winkelmann, Winfried; Kotz, Rainer
Author(s) at UniBasel Jundt, Gernot
Kühne, Thomas
Year 2009
Title Osteosarcoma: the COSS experience
Journal Cancer treatment and research
Volume 152
Pages 289-308
Abstract COSS, the interdisciplinary Cooperative German-Austrian-Swiss Osteosarcoma Study Group, was founded in 1977 and has since registered some 3,500 bone sarcoma patients from over 200 institutions. For the purpose of the Pediatric and Adolescent Osteosarcoma Conference in Houston, March 2008, the outcomes of 2,464 consecutive patients with high-grade central osteosarcoma, who had been diagnosed between 1980 and 2005 and had been treated on neoadjuvant COSS protocols, were reviewed. Intended treatment had included surgery and multidrug chemotherapy, with high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide being used in most protocols. After a median follow-up of 7.31 years for 1,654 survivors, 5- and 10-year survival estimates were 0.748/0.695 for 2,017 patients with localized extremity tumors and 0.369/0.317 for 444 patients with axial tumors or/and primary metastases, respectively. Tumor response to preoperative chemotherapy was of independent prognostic significance. Over the years, there was a major shift from amputation towards limb-salvage. This development was least evident for patients below the age of 10. While survival expectancies improved from the first to the second half of the recruitment period, no further improvement was evident within the latter period. In the manuscript, the results described above are discussed based on the findings of the previous analyses of our group.
Publisher SPRINGER
ISSN/ISBN 0927-3042
edoc-URL http://edoc.unibas.ch/dok/A6007566
Full Text on edoc No
Digital Object Identifier DOI 10.1007/978-1-4419-0284-9_15, 10.1007/978-1-4419-0284-9_15
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/20213397
ISI-Number WOS:000273510800015
Document type (ISI) Proceedings Paper
Additional Information Also published in: Pediatric and adolescent osteosarcoma. - New York : Springer, 2010. - S. 289-308
 
   

MCSS v5.8 PRO. 0.353 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
29/03/2024